Compare Inovio Pharmaceuticals Inc (INO) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nokia Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Nokia Corp trades at $10.36 (market cap $56.99B). The key difference: Nokia Corp is far larger — about 508× Inovio Pharmaceuticals Inc's market cap, and Nokia Corp pays a 1.61% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Nokia Corp for 66 Days on average.
| INO | NOK | |
|---|---|---|
Market Cap | $112.19M | $56.99B |
Volume | 3,201,278 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $2.60 | $16.83 |
52-Week Low | $0.66 | $5.25 |
Typical Hold Time | 43 Days | 66 Days |
Enterprise Value | $83.51M | $55.01B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Nokia (NOK) trades at $10.14, down 4.52% today, amid bearish technical signals but strong analyst support. The stock shows mixed fundamentals with a high P/E ratio of 75.09 but improving revenue trends, with 2026 revenue projected at $20.4B. Recent partnerships with Microsoft and ICEYE for AI and satellite communications highlight growth initiatives. Cash flow volatility remains a concern with negative net cash flow in 2025 and 2026.
The outlook is cautiously optimistic with a consensus price target of $17.50 representing 73% upside potential. Key opportunities include AI infrastructure demand and expanding partnerships, while risks involve cash flow instability and competitive pressures in telecom equipment. Analyst sentiment is strongly bullish with 62% buy ratings, though technical indicators suggest near-term weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
